Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Pavla Röselová, Adam Obr, Aleš Holoubek, Dana Grebeňová & Kateřina Kuželová. (2018) Adhesion structures in leukemia cells and their regulation by Src family kinases. Cell Adhesion & Migration 12:3, pages 286-298.
Read now
Read now
Françoise Huguet. (2015) Dasatinib for acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs 3:11, pages 1339-1356.
Read now
Read now
Cristina Varallo-Rodriguez, Craig W Freyer, Evelena P Ontiveros, Elizabeth A Griffiths, Eunice S Wang & Meir Wetzler. (2015) Bosutinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opinion on Orphan Drugs 3:5, pages 599-608.
Read now
Read now
Kendra Sweet, Javier Pinilla-Ibarz & Ling Zhang. (2014) Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Preference and Adherence 8, pages 981-986.
Read now
Read now
Francesca Rusconi, Rocco Piazza, Elisabetta Vagge & Carlo Gambacorti-Passerini. (2014)
Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opinion on Pharmacotherapy 15:5, pages 701-710.
Read now
Read now
Gunhild Keller-von Amsberg & Steffen Koschmieder. (2013) Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. OncoTargets and Therapy 6, pages 99-106.
Read now
Read now
Gunhild Keller-von Amsberg & Philippe Schafhausen. (2013) Bosutinib in the management of chronic myelogenous leukemia. Biologics: Targets and Therapy 7, pages 115-122.
Read now
Read now
Gunhild Keller-v.Amsberg & Tim H Brümmendorf. (2012) Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Review of Anticancer Therapy 12:9, pages 1121-1127.
Read now
Read now
Tugce Bulakbasi Balci, Feride Iffet Sahin, Sema Karakus & Hakan Ozdogu. (2011) AHI1 gene expression levels and BCR-ABL1
T315I mutations in chronic myeloid leukemia patients. Hematology 16:6, pages 357-360.
Read now
Read now
Daniela Cilloni, Emanuela Messa, Antonia Rotolo & Giuseppe Saglio. (2010) Emerging drugs for chronic myeloid leukemia. Expert Opinion on Emerging Drugs 15:2, pages 175-184.
Read now
Read now
Gunhild Keller, Philippe Schafhausen & Tim H Brummendorf. (2009) Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Review of Hematology 2:5, pages 489-497.
Read now
Read now
Articles from other publishers (61)
Sana Ansari & Malkhey Verma. (2023) Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors. Medical Oncology 40:8.
Crossref
Crossref
Xu Zhang, Linglan Tu, Haohuan Chai, Zilin Li, Yuhan Fu, Xiaoliang Zheng, Shenxin Zeng & Liyan Cheng. (2022) The Activity of Novel BCR-ABL Small-Molecule Degraders Containing Pyrimidine Rings and Their Role in Overcoming Drug Resistance. Journal of Oncology 2022, pages 1-11.
Crossref
Crossref
Ioanna Lazana. (2022) Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?. International Journal of Molecular Sciences 23:17, pages 10118.
Crossref
Crossref
H. Jonathan G. Lindström & Ran Friedman. (2022) Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model. Scientific Reports 12:1.
Crossref
Crossref
BaniBandana Ganguly, Shouvik Mandal, Debasis Banerjee & NitinN Kadam. (2022) Effects of tyrosine kinase inhibitors for controlling Ph+ clone and additional clonal abnormalities in a chronic myeloid leukemia. Journal of Cancer Research and Therapeutics 18:3, pages 760.
Crossref
Crossref
Radhika Takiar, Charles E. Foucar, Anthony J. Perissinotti, Bernard L. Marini, Lydia Benitez-Colon, Patrick W. Burke & Dale L. Bixby. (2022) Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation–A single institution experience. Leukemia Research Reports 18, pages 100352.
Crossref
Crossref
Gurjeet Kaur, Rahul Soloman Singh, Ashutosh Singh, Harvinder Singh, Shweta Sinha & Bikash Medhi. 2022. Biomedical Translational Research. Biomedical Translational Research
349
366
.
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, António M. Almeida, Javier De Las Rivas, Ioannis P. Trougakos & Ana Bela Sarmento Ribeiro. (2021) Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. Cancers 13:19, pages 4820.
Crossref
Crossref
Nilüfer Bayrak, Halil I. Ciftci, Mahmut Yıldız, Hatice Yıldırım, Belgin Sever, Hiroshi Tateishi, Masami Otsuka, Mikako Fujita & Amaç Fatih Tuyun. (2021) Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs. Chemico-Biological Interactions 345, pages 109555.
Crossref
Crossref
Luca Mologni, Giovanni Marzaro, Sara Redaelli & Alfonso Zambon. (2021) Dual Kinase Targeting in Leukemia. Cancers 13:1, pages 119.
Crossref
Crossref
Caitlyn A. Moore, Alejandra I. Ferrer, Sara Alonso, Sri Harika Pamarthi, Oleta A. Sandiford & Pranela Rameshwar. 2021. Tumor Microenvironment: Cellular, Metabolic and Immunologic Interactions. Tumor Microenvironment: Cellular, Metabolic and Immunologic Interactions
67
89
.
Bryan T. Ciccarelli, Tinghui Hu, Qing Wang, Julia J. Kim & Ian P. Whitehead. (2020) Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML. Leukemia Research 97, pages 106440.
Crossref
Crossref
Ancuta Jurj, Sergiu Pasca, Patric Teodorescu, Ciprian Tomuleasa & Ioana Berindan-Neagoe. (2020) Basic knowledge on BCR-ABL1-positive extracellular vesicles. Biomarkers in Medicine 14:6, pages 451-458.
Crossref
Crossref
Bani Bandana Ganguly & Nitin N. Kadam. (2019) Genetics and tyrosine kinase inhibitors of chronic myeloid leukemia. The Nucleus 62:2, pages 155-164.
Crossref
Crossref
Jie Sun, Jing Wang, Na Zhang, Renjun Yang, Keyang Chen & Derun Kong. (2019) Identification of global mRNA expression profiles and comprehensive bioinformatic analyses of abnormally expressed genes in cholestatic liver disease. Gene 707, pages 9-21.
Crossref
Crossref
Jeremy Chang, Dan Douer, Ibrahim Aldoss, Golnaz Vahdani, Ah‐Reum Jeong, Zunera Ghaznavi, Sherry Zhang, George Yaghmour, Kum‐Ja Lee, Ashley Weissman & Mojtaba Akhtari. (2019) Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse‐free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia. Cancer Medicine 8:6, pages 2832-2839.
Crossref
Crossref
Neetu Singh, Anil Kumar Tripathi, Dinesh Kumar Sahu, Archana Mishra, Margaret Linan, Bianca Argente, Julia Varkey, Niranjan Parida, Rebecca Chowdhry, Hari Shyam, Nawazish Alam, Shivani Dixit, Pratap Shankar, Abhishek Mishra, Avinash Agarwal, Chris Yoo, Madan Lal Brahma Bhatt & Ravi Kant. (2018) Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia. Oncotarget 9:54, pages 30385-30418.
Crossref
Crossref
Mi Seon Kim, Byong Chul Yoo, Woo Seok Yang, Sang Yun Han, Deok Jeong, Jun Min Song, Kyung Hee Kim, Adithan Aravinthan, Ji Hye Kim, Jong-Hoon Kim, Seung Cheol Kim & Jae Youl Cho. (2017) Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget 9:5, pages 5979-5992.
Crossref
Crossref
Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf & Dominik Wolf. 2018. Small Molecules in Hematology. Small Molecules in Hematology
87
108
.
Lingdi Ma, Zhenyu Xu, Jian Wang, Zhichao Zhu, Guibin Lin, Lijia Jiang, Xuzhang Lu & Chang Zou. (2017) Matrine inhibits BCR/ABL mediated ERK/MAPK pathway in human leukemia cells. Oncotarget 8:65, pages 108880-108889.
Crossref
Crossref
Bogdan Ochrem & Tomasz Sacha. (2017) Efficacy and safety of bosutinib in the second and third line of treatment in chronic myeloid leukemia. Acta Haematologica Polonica 48:4, pages 274-281.
Crossref
Crossref
Priscila J. Carneiro, Amanda L. Clevelario, Gisele A. Padilha, Johnatas D. Silva, Jamil Z. Kitoko, Priscilla C. Olsen, Vera L. Capelozzi, Patricia R. M. Rocco & Fernanda F. Cruz. (2017) Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis. Frontiers in Physiology 8.
Crossref
Crossref
Gillian M. Keating. (2016) Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia. Drugs 77:1, pages 85-96.
Crossref
Crossref
Ying Hong Li, Pan Pan Wang, Xiao Xu Li, Chun Yan Yu, Hong Yang, Jin Zhou, Wei Wei Xue, Jun Tan & Feng Zhu. (2016) The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective. PLOS ONE 11:11, pages e0165737.
Crossref
Crossref
Xavier Thomas & Maël Heiblig. (2016) Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematologic Oncology 5:2, pages 77-90.
Crossref
Crossref
Jianbiao Zhou, Sam Wang, Kangyun Sun & Wee-Joo Chng. (2016) The emerging roles of exosomes in leukemogeneis. Oncotarget 7:31, pages 50698-50707.
Crossref
Crossref
Ami Patel, Harika Sabbineni, Andrea Clarke & Payaningal R. Somanath. (2016) Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sciences 157, pages 52-61.
Crossref
Crossref
Tim H. Brümmendorf, Jorge E. Cortes, Hanna J. Khoury, Hagop M. Kantarjian, Dong‐Wook Kim, Philippe Schafhausen, Maureen G. Conlan, Mark Shapiro, Kathleen Turnbull, Eric Leip, Carlo Gambacorti‐Passerini & Jeff H. Lipton. (2015) Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology 172:1, pages 97-110.
Crossref
Crossref
Cinzia Maria Francini, Anna Lucia Fallacara, Roberto Artusi, Laura Mennuni, Alessia Calgani, Adriano Angelucci, Silvia Schenone & Maurizio Botta. (2015) Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. ChemMedChem 10:12, pages 2027-2041.
Crossref
Crossref
Sanam Loghavi, Jeffery L. KutokJeffrey L. Jorgensen. (2015) B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. American Journal of Clinical Pathology 144:3, pages 393-410.
Crossref
Crossref
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, Hagop Kantarjian, Martha Arellano, Emily A. Knight, Hao Xiong, Qin Qin, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Daniel H. Albert, Brian Oliver, Mark D. McKee, Justin L. Ricker & Hanna Jean Khoury. (2015) Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs 33:4, pages 870-880.
Crossref
Crossref
Osamu Tomita, Kazutoshi Iijima, Takeshi Ishibashi, Tomoo Osumi, Kenichiro Kobayashi, Hajime Okita, Masahiro Saito, Tetsuya Mori, Toshiaki Shimizu & Nobutaka Kiyokawa. (2014) Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1. Leukemia Research 38:3, pages 361-370.
Crossref
Crossref
Shin Fujisawa, Hirohisa Nakamae, Michinori Ogura, Ken-ichi Ishizawa, Masafumi Taniwaki, Atae Utsunomiya, Kosei Matsue, Yasushi Takamatsu, Kensuke Usuki, Mitsune Tanimoto, Yoji Ishida, Hideki Akiyama & Shintaro Onishi. (2013) Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. International Journal of Hematology 99:2, pages 141-153.
Crossref
Crossref
Susanne Isfort, Gunhild Keller-v. Amsberg, Philippe Schafhausen, Steffen Koschmieder & Tim H. Brümmendorf. 2014. Small Molecules in Oncology. Small Molecules in Oncology
81
97
.
Rosalyn B. Irby & Timothy J. Yeatman. 2015. Molecular Oncology. Molecular Oncology
231
242
.
Victoria Campbell & Mhairi Copland. (2013) Dasatinib for the treatment of chronic phase chronic myeloid leukemia. Clinical Practice 10:4, pages 415-425.
Crossref
Crossref
Jin Cai, Min Sun, Xiaoqing Wu, Junqing Chen, Peng Wang, Xi Zong & Min Ji. (2013) Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents. European Journal of Medicinal Chemistry 63, pages 702-712.
Crossref
Crossref
Se Eun Byeon, Tao Yu, Yanyan Yang, Yong Gyu Lee, Ji Hye Kim, Jueun Oh, Hye Yoon Jeong, Suntaek Hong, Byong Chul Yoo, Won-Jea Cho, Sungyoul Hong & Jae Youl Cho. (2013) Hydroquinone regulates hemeoxygenase-1 expression via modulation of Src kinase activity through thiolation of cysteine residues. Free Radical Biology and Medicine 57, pages 105-118.
Crossref
Crossref
Ji Hye Kim, Yong Gyu Lee, Seungwan Yoo, Jueun Oh, Deok Jeong, Woo Keun Song, Byong Chul Yoo, Man Hee Rhee, Jongsun Park, Sang-hoon Cha, Sungyoul Hong & Jae Youl Cho. (2013) Involvement of Src and the actin cytoskeleton in the antitumorigenic action of adenosine dialdehyde. Biochemical Pharmacology 85:8, pages 1042-1056.
Crossref
Crossref
Keith B. Glaser, Junling Li, Patrick A. Marcotte, Terrance J. Magoc, Jun Guo, David R. Reuter, Paul Tapang, Ru-Qi Wei, Lori J. Pease, Mai H. Bui, Zehan Chen, Robin R. Frey, Eric F. Johnson, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Yanping Luo, Michael L. Curtin, Cherrie K. Donawho, Michael R. Michaelides, Chris Tse, Steven K. Davidsen & Daniel H. Albert. (2012) Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families. Journal of Pharmacology and Experimental Therapeutics 343:3, pages 617-627.
Crossref
Crossref
Theresa Liu-Dumlao, Hagop Kantarjian, Deborah A. Thomas, Susan O’Brien & Farhad Ravandi. (2012) Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options. Current Oncology Reports 14:5, pages 387-394.
Crossref
Crossref
Jos? E. V?zquez-Franco, Elba Reyes-Maldonado, Jorge Vela-Ojeda, Maria L. Dom?nguez-L?pez & Ruth A. Lezama. (2012) Src, Akt, NF-?B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia. Leukemia Research 36:7, pages 862-867.
Crossref
Crossref
Hilmar Quentmeier, Sonja Eberth, Julia Romani, Margarete Zaborski & Hans G Drexler. (2011) BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. Journal of Hematology & Oncology 4:1.
Crossref
Crossref
Marco Radi, Elena Dreassi, Chiara Brullo, Emmanuele Crespan, Cristina Tintori, Vincenzo Bernardo, Massimo Valoti, Claudio Zamperini, Henry Daigl, Francesca Musumeci, Fabio Carraro, Antonella Naldini, Irene Filippi, Giovanni Maga, Silvia Schenone & Maurizio Botta. (2011)
Design, Synthesis, Biological Activity, and ADME Properties of Pyrazolo[3,4-
d
]pyrimidines Active in Hypoxic Human Leukemia Cells: A Lead Optimization Study
. Journal of Medicinal Chemistry 54:8, pages 2610-2626.
Crossref
Crossref
Farhad Ravandi. (2011) Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma and Leukemia 11:2, pages 198-203.
Crossref
Crossref
Shekhar Krishnan, Ashish Masurekar & Vaskar Saha. 2011. New Agents for the Treatment of Acute Lymphoblastic Leukemia. New Agents for the Treatment of Acute Lymphoblastic Leukemia
25
37
.
Eric I. Zimmerman, Claudia M. Dollins, Melissa Crawford, Steven Grant, Serge P. Nana-Sinkam, Kristy L. Richards, Scott M. Hammond & Lee M. Graves. (2010) Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia. Molecular Pharmacology 78:5, pages 811-817.
Crossref
Crossref
Con Sullivan, Cong Peng, Yaoyu Chen, Dongguang Li & Shaoguang Li. (2010) Targeted therapy of chronic myeloid leukemia. Biochemical Pharmacology 80:5, pages 584-591.
Crossref
Crossref
Fabrizio Condorelli & Armando A. Genazzani. (2010) Dasatinib. BioDrugs 24:3, pages 157-163.
Crossref
Crossref
Xiao Hua Ma, Zhe Shi, Chunyan Tan, Yuyang Jiang, Mei Lin Go, Boon Chuan Low & Yu Zong Chen. (2010) In-Silico Approaches to Multi-target Drug Discovery. Pharmaceutical Research 27:5, pages 739-749.
Crossref
Crossref
Michael B. Lilly, Oliver G. Ottmann, Neil P. Shah, Richard A. Larson, Josy J. Reiffers, Gerhard Ehninger, Martin C. Müller, Aude Charbonnier, Eduardo Bullorsky, Herve Dombret, Mary Brigid Bradley‐Garelik, Chao Zhu & Giovanni Martinelli. (2010) Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. American Journal of Hematology 85:3, pages 164-170.
Crossref
Crossref
Gunhild Keller, Philippe Schafhausen & Tim H. Brümmendorf. 2010. Small Molecules in Oncology. Small Molecules in Oncology
119
127
.
Jiyuan Ke, R Lakshman Chelvarajan, Vishal Sindhava, Darrell A Robertson, Lazaros Lekakis, C Darrell Jennings & Subbarao Bondada. (2009) Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Molecular Cancer 8:1.
Crossref
Crossref
Hong-Yun Jia, Jiang-Xue Wu, Xiao-Feng Zhu, Jie-Min Chen, Shi-Ping Yang, Hai-Jiao Yan, Li Tan, Yi-Xin Zeng & Wenlin Huang. (2009) ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leukemia Research 33:11, pages 1512-1519.
Crossref
Crossref
Fei Huang & Edwin A. Clark. 2009. Kinase Inhibitor Drugs. Kinase Inhibitor Drugs
365
402
.
Alfonso Quintás-Cardama, Jorge E. Cortes, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai-Tsang Chen & Hagop M. Kantarjian. (2009) Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115:13, pages 2912-2921.
Crossref
Crossref
Yutaka Fujii, Manabu Amano & Taku Seriu. (2009) Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel<sup>®</sup>), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Folia Pharmacologica Japonica 134:3, pages 159-167.
Crossref
Crossref
Oliver G. Ottmann & Heike Pfeifer. (2009) Management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Hematology 2009:1, pages 371-381.
Crossref
Crossref
Heiko Konig, Mhairi Copland, Su Chu, Richard Jove, Tessa L. Holyoake & Ravi Bhatia. (2008) Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research 68:23, pages 9624-9633.
Crossref
Crossref
Anthony Jarkowski & Richard P. Sweeney. (2012) Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:11, pages 1374-1382.
Crossref
Crossref
Ryuzo Ohno. (2008) Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Current Oncology Reports 10:5, pages 379-387.
Crossref
Crossref